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ABSTRACT 
Purpose: To study the immunomodulatory activity of aqueous and ethanol extracts of leaves of Abutilon 
indicum Linn. (Family: Malvaceae) on albino mice.  
Methods: The ethanolic and aqueous extract of leaves of Abutilon indicum was administered orally at the 
dosage levels of 200 mg/kg/day and 400 mg/kg/day body weight in mice. The assessment of 
immunomodulatory activity on specific and non-specific immunity were studied by heamagglutination antibody 
(HA) titer, delayed type hypersensitivity (DTH), neutrophil adhesion test and carbon clearance test. In order to 
induced immunosuppresion in mice by using cyclophosphamide (100 mg/kg/day, p.o.) and levamisole (50 
mg/kg/day, p.o.) used as immunostimulating agents.  
Results: Oral administration of A. indicum showed a significant increase in the production of circulating 
antibody titre in response to sheep red blood cells (SRBCs). A significant (p<0.01) increase in both primary and 
secondary HA titre was observed when compared to control group, whereas in cyclophosphamide treated group 
A. indicum showed significant (p<0.01) increase in HA titre. A. indicum showed significantly (p<0.01) 
potentiated the DTH reaction by facilitating the footpad thickness response to SRBCs in sensitized mice. Also 
A. indicum evoked a significant (p<0.01) increase in percentage neutrophil adhesion to nylon fibers and 
phagocytic activity.  
Conclusion: The study demonstrates that A. indicum triggers both specific and non-specific responses to a 
greater extent. The study comprised the acute toxicity and preliminary phytochemical screening of A. indicum. 
From the results obtained and phytochemical studies the immunostimulant effect of AI could be attributed to the 
flavonoid content.  
Keywords:  Abutilon indicum, Immunomodulation, antibody titre, delayed type hypersensitivity, phagocytic 
index. 
INTRODUCTION 
Indian traditional systems of medicines like Siddha and Ayurveda have suggested to increase the body’s natural 
resistance to disease.
[1] Recent screening with plants has revealed many compounds (e.g. alkaloids, flavonoids, 
quinones, terpenoids) with pronounced antioxidant, antineoplastic, antiulcer, anti-inflammatory and 
immunostimulating potential.
[2] 
Abutilon indicum (AI) commonly known as “Atibala” in Sanskrit gives excessive tonic strength.
 [3] Atibala is a 
stronger diuretic and heart tonic.
[4] AI reported in the Siddha system as a remedy for jaundice, piles, ulcer, 
leprosy, rakttapitta dosha and blood purifier.
[5-6] Chemically it contains flavonoids (quercetin), saponins, 
alkaloids and phenolic compounds.
[7] Hence, the present study evaluating immunomodulatory activity of AI.  
MATERIALS AND METHODS 
Plant material 
The fresh whole plant of AI used in this study, collected at the flowering stage (month : September) from local 
area of Sangli, Maharashtra state, India and authenticated by Dr. U. S. Yadav of the Department of Botany, 
Willingdon College, Sangli, where a voucher specimen has been preserved for future identification.  
Extraction 
The leaves were separated from the fresh stems and dried on filter paper sheets under shade at room temperature 
until with changing of color of filter papers. The shade-dried, coarsely powdered leaves (500g) were 
successively extracted with petroleum ether (60-80
o) for 8 hr. to remove fatty matter. The defatted marc was 
then subjected to soxhlet extraction with 95% ethanol to obtain ethanolic extract. The dried marc was cold 
macerated with distilled water and chloroform (9:1) for 7 days to obtain aqueous extract. The both ethanolic and 
aqueous extracts were evaporated under reduced pressure at low temperature (30
0C) to dryness to yield 
yellowish brown color extracts of AI, stored in an airtight container in refrigerator for further experimental 
studies.  
Preliminary phytochemical screening 
Aqueous and ethanolic extracts of AI were subjected to preliminary phytochemical screening using the methods 
described by Kokate, Trease and Evans for the detection of various plants constituent.
 [8-9] 
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Animals  
Inbred colony of swiss albino mice of weighing between 20-25 gm were housed in groups of 5 to 6. All mice 
were fed with pelleted diet (Pranav Agro Industries Ltd, Sangli, India) and tap water ad libitum. Institutional 
Animals Ethics Committee (IAEC) approved the experimental protocol and care of animals was taken as per 
guidelines of CPCSEA, Department of Animal Welfare, and Government of India. (843/ac/04/ CPCSEA). 
Drugs and chemicals 
All the drugs and chemicals were of analytical grade while the other drugs were procured from Levamisole 
(Khandelwal Pharmaceutical Ltd. Mumbai), Cyclophosphamide (Biochem pharmaceutical, Mumbai), Colloidal 
carbon (Indian ink, camel India Pvt. Ltd.).  
Test compound formulations 
The dilution of aqueous extract of leaves of AI  (AEAI) was prepared in distilled water and the aqueous 
suspension of ethanolic extract of leaves of AI (EEAI) was prepared in 0.5 % carboxymethylcellulose (CMC) 
solution in distilled water prior to oral administration to animals. It was used within 7 days and stored at 8
0C 
while for further use, freshly prepared solution was used. The vehicle alone served as control. 
Acute toxicity studies 
Acute toxicity studies were performed according to organization for economic cooperation and development 
(OECD) guidelines, received draft guidelines 425, received from CPCSEA, Ministry of social justice and 
empowerment, Government of India.
[10] Mice weighing between 20-25 gm in groups of five were used (n=5). 
The animals were fasted for 4 hr. with free access to water only. The both EEAI and AEAI extracts was 
administered orally in doses of 2000 and 5000 mg/kg to different groups of mice and observed over 14 days for 
mortality and physical/behavioral changes. The experiments were performed after the experimental protocols 
had been approved by the Institutional Animal Ethical committee. 
Thin layer chromatography 
TLC studies were carried out on the EEAI for flavonoids, using silica gel G TLC plates as the stationary phase 
and Chloroform : benzene : Ethanol : acetic acid : water (11 : 4 : 2 : 1 : 2 ) as the mobile phase. The TLC plates 
were spotted using the glass capillary and developed by spraying with ninhydrin reagent resulted in the 
formation of bright yellow spot indicating the presence of flavonoids in this extract.
 [11] 
Experimental procedure 
Antigenic material: Preparation of Sheep RBCs (SRBCs) 
Sheep blood was collected in sterile Alsevere’s solution in 1:1 proportion of Alsevere’s solution (freshly 
prepared). Blood was kept in the refrigerator and processed, for the preparation of SRBCs batch, by 
centrifugating at 2000 rpm for 10 minutes and washing with physiological saline 4-5 times and then suspending 
into buffered saline for further use.
 [12] 
Carbon ink suspension: Pelican AG, Germany, ink was diluted eight times with saline and used for carbon 
clearance test in a dose of 10µl/gm body weight of mice.
[13] 
Haemagglutination antibody (HA) titer 
[14] 
The mice were divided into eight groups consisting of five animals each. Mice in group I received vehicle only 
for 21 days. Group II received cyclophosphamide (Negative Control) 100 mg/kg, p.o. on 9
th and 16
th day as a 
single dose. Mice in treatment group III and IV were given AEAI (400 mg/kg/day/p.o) and EEAI (200 
mg/kg/day/p.o.) daily for 21 days respectively. Immunosuppresed animals in group V and VI were given AEAI 
(400 mg/kg/day/p.o) and EEAI (200 mg/kg/day/p.o.) plus cyclophosphamide (100 mg/kg/p.o.) on 9
th and 16
th 
day as a single dose respectively. Group VII received standard drug levamisole (50 mg/kg/p.o.) as an established 
immunostimulant agent for 21 days and group VIII received levamisole (50 mg/kg/p.o.) for 21 days plus 
cyclophosphamide (100 mg/kg/p.o.) on 9
th and 16
th day as a single dose.  
On 7
th and 14
th day of the study, mice from all the groups (i.e. group I to VIII) were immunized and challenged 
respectively, with SRBCs in normal saline (0.1ml of 20% SRBCs) intraperitoneally. Blood was withdrawn on 
14
th and 21
st day from retro-orbital plexus under mild ether anaesthesia from all antigenically sensitised and 
challenged mice respectively. Blood was centrifuged to obtain serum, normal saline was used as a diluent and 
SRBCs count was adjusted to (0.1% of SRBCs). Each well of a microtitre plate was filled initially with 20 µl of 
saline and 20 µl of serum was mixed in the first well of micro titre plate. Subsequently the 20 µl diluted serum 
was removed from first well and added to the  next well to get twofold dilutions of the antibodies present in the 
serum. Further twofold dilutions of this diluted serum were similarly carried out till the last well of the second 
row (24
th well), so that the antibody concentration of any of the dilutions is half of the previous dilution. 20 µl 
SRBC (0.1% of SRBCs) were added to each of these dilutions and the plates were incubated at 37°C for one 
hour and then observed for haemagglutination. The highest dilution giving haemagglutination was taken as the 
antibody  titre. The antibody titres were expressed in the graded manner, the minimum dilution (1/2) being 
ranked as 1, and mean ranks of different groups were compared for statistical significance. Antibody titre 
obtained on 14
th day after immunization (on 7
th day) and on 21
st day after challenge (on 14
th day) with SRBCs 
was considered as primary and secondary humoral immune response respectively.   
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Delayed type hypersensitivity (DTH) response 
[15-16] 
The drug treatment was exactly the same as described above for HA titer. On 14
th day of the study, all the 
groups I to VIII were immunized with SRBCs (0.1ml of 20% SRBC i.p.) in normal saline. On day 21
st all 
animals from all the groups were challenged with 0.03 ml of 20% SRBCs in subplantar region of right hind paw. 
Foot pad oedema in mice was used for detection of cellular immune response. On 21
st day, injection of 0.1ml of 
20% SRBCs in the subplantar region of right hind paw in the volume of 0.03 ml and normal saline in left hind 
paw in same volume. Foot pad reaction was assessed after 24 hr. on 22
nd day, in terms of increase in the 
thickness of footpad as a result of hypersensitivity reaction due to oedema, the thickness of the right hind 
footpad was measured using vernier calliper. The footpad reaction was expressed as the difference in the 
thickness (m.m.) between the right foot pad injected with SRBC and the left footpad injected with normal saline. 
Neutrophil adhesion test
[17] 
Mice were divided into four groups of five animals each. The control group I received vehicle, while animals of 
treatment group II and III were given AEAI (400 mg/kg/day/p.o.) and EEAI (200 mg/kg/day/p.o.) daily for 14 
days respectively. Group IV received levamisole (50 mg/kg/p.o.) for 14 days. On the 14
th day of the treatment, 
blood samples from all the groups were collected by puncturing retro-orbital plexus under mild ether 
anaesthesia. Blood was collected in vials pre-treated by disodium EDTA and analysed for total leukocyte count 
(TLC) and differential leukocyte count (DLC) by fixing blood smears and staining with Leishman’s stain. After 
initial counts, blood samples were incubated with nylon fiber (80 mg/ml of blood sample) for 15 min at 37
0C. 
The incubated blood samples were again analyzed for TLC and DLC. The product of TLC and % neutrophil 
gives neutrophil index (NI) of blood sample. Percent neutrophil adhesion was calculated as follows, 
UT
U
   NI - NI x 100
Neutrophil adhesion=
NI
 
Where, 
NIU : Neutrophil Index before incubation with nylon fiber. 
NIT  : Neutrophil Index after incubation with nylon fiber. 
 
Carbon clearance test
[18] 
The drug treatment was exactly the same as with the neutrophil adhesion test as described above. On 14
th day, 3 
hours after the last dose all the animals of each group were given colloidal carbon intravenously in a volume of 
1 ml/100 g. Blood samples were then withdrawn (25 µl) from retro-orbital plexus at 0 and 15 minutes  after 
injection of colloidal carbon ink and lysed in sodium carbonate solution (3 ml). The optical density was 
measured spectrophotometrically at 650 nm. The phagocytic index (K) was calculated using the formula:  
K  =        (In OD1 – In OD2) 
          (t2 – t1) 
Where, OD1 and OD2 are the optical densities at time t1 and t2 respectively. 
Statistical Analysis 
All the results were expressed as Mean±Standard Error (SEM). Data were analyzed using one-way Analysis of 
Variance (ANOVA) followed by Tukey-Kramer multiple comparison test. p-values <0.01 were considered as 
statistically significant. 
RESULTS 
Acute oral toxicity study 
Acute oral toxicity was carried out by up-down regulation method. It is found that AEAI and EEAI were safe at 
limit dose 4000 mg/kg and 2000 mg/kg, with no mortality in studied subjects respectively. 1/10
th of this dose i.e. 
400 mg/kg and 200 mg/kg for AEAI and EEAI was used in the subsequent study respectively.  
TLC for flavonoids 
The naked eyes observed spot in bright yellow colored and in UV chamber spot observed in fluorescent yellow 
colored. Rf (× 100) value for the EEAI was found to be as 77 and 65 which is the near the Rf value for flavanol 
and flavones.  
Preliminary phytochemical screening 
The presence of various phytoconstituents of the extracts was detected by phytochemical screening. The AEAI 
found to contain carbohydrates, proteins, amino acids and flavonoids. The EEAI were found to contain 
carbohydrates, proteins, amino acids, saponin glycosides, flavonoids, alkaloids, tannins and phenolic 
compounds.         
Haemagglutination antibody [HA] titre 
Effect of AEAI and EEAI on primary and secondary antibody response on HA titre is shown in [Table 1]. 
Primary antibody response on day 14
th in AEAI (400 mg/kg/p.o.) treated group with normal immune status 
showed significant increase (P<0.01) in HA titer titre when compared with the control group. A significant 
decrease (P<0.01) in the antibody titre was observed in the cyclophosphamide-treated group when compared 
ISSN : 0975-9492 180N.L. DASHPUTRE et. al. / International Journal of Pharma Sciences and Research (IJPSR) 
Vol.1(3), 2010, 178-184 
with the control group. In immunosuppressed groups, where the immunity was suppressed by administration of 
cyclophosphamide on day nine, EEAI (200 mg/kg/p.o.) administration produced a significant (P<0.01) rise in 
the antibody titre when compared with the cyclophosphamide-treated group. Secondary antibody titre on 
twenty-first day in AEAI and EEAI-treated groups with normal immune status group showed a significant rise 
(P<0.01) in the antibody titre when compared with the control group. In the immunosuppresed groups where the 
immunity was suppressed by administration of cyclophosphamide on day sixteenth
 AEAI and EEAI showed a 
significant rise (P<0.01) in HA titer when compared with the cyclophosphamide group. 
Table  1. Effect of A.indicum on primary and secondary antibody titre. 
Treatment        Primary antibody titre            Secondary antibody titre            
Vehicle Control                                4.00 ± 0.577                             5.66 ± 0.88 
Cyp-treated (Negative control)  3.00 ± 0.577** a                       4.66 ± 0.33** a 
AEAI  7.00 ± 0.57** a                         8.00 ± 0.57** a 
EEAI       6.00 ± 0.57                               8.66 ± 0.33** a 
LMS      8.00 ± 0.57** a                         8.66 ± 0.88**a  
AEAI + Cyp.                                    5.33 ± 0.88                               7.33 ± 0.33 
EEAI + Cyp.                                    6.33 ± 0.33** b                         7.66 ± 0.33** b 
LMS + Cyp.                                     7.33 ± 0.57** b                         8.33 ± 0.33** b 
The values are expressed as ( Mean ± S.E.M.), n= 5, ** p< 0.01. 
a: Cyp :Cyclophosphamide, only normal immune status groups i.e, AEAI, EEAI and LMS-treated groups were 
compared with vehicle control (Group I). b: Immunosuppressed test extract of AEAI, EEAI, LMS + Cyp. 
treated groups were compared with negative control (GroupII).  
Delayed Type Hypersensitivity 
Effect of AEAI and EEAI on cell mediated immune response by DTH induced footpad oedema is shown in 
[Table 2]. On twenty-first day cyclophosphamide-treated group showed significant (p<0.01) decrease in the 
mean difference of paw thickness when compared to control group. In the all groups of mice with normal 
immune status, of AEAI (400 mg/kg/p.o.) and EEAI (200 mg/kg/p.o.) showed significant (p<0.01) potentiated 
DTH response in terms of increase in the mean difference of paw thickness when compared with control group. 
In the all groups of mice treated with cyclophosphamide i.e. an immunosuppressed groups are, AEAI and EEAI 
showed significant (p<0.01) potentiated DTH response in terms of increase in the mean difference of paw 
thickness when compared with cyclophosphamide (negative control) group. Heightened delayed type 
hypersensitivity reaction suggests activation of cellular immune system. 
Table 2.  Effect of A.indicum treatment on cell mediated immune response by delayed type hypersensitivity 
induced footpad oedema. 
Treatment        Mean diff.of paw oedema  in (mm) 
Vehicle Control                           0.293 ± 0.088 
Cyp-treated (Negative control)  0.445 ± 0.0035**a 
AEAI  0.914 ± 0.0047**a 
EEAI       0.992 ± 0.003** a
LMS      0.952 ± 0.003**a 
AEAI + Cyp.                               0.527 ± 0.035**b 
EEAI + Cyp.                                0.863 ± 0.007**b 
LMS + Cyp.                                 0.956 ± 0.004**b 
The values are expressed as ( Mean ± S.E.M.), n= 5, ** p< 0.01. 
a: Cyp :Cyclophosphamide, only normal immune status groups i.e, AEAI, EEAI and LMS-treated groups were 
compared with vehicle control (Group I). b: Immunosuppressed test extract of AEAI, EEAI, LMS + Cyp. 
treated groups were compared with negative control (GroupII).  
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Carbon Clearance Test 
Effect of AEAI and EEAI on the phagocytic activity by the carbon clearance test is shown in [Table 3]. The 
phagocytic activity of the reticulo-endothelial system is generally measured by the rate of removal of carbon 
particles from the blood stream. In carbon clearance test, AI treated all groups, exhibited significantly high 
phagocytic index. The phagocytic index of AEAI (400 mg/kg/p.o.) and EEAI (200 mg/kg/p.o.) showed 
significant (p<0.01) increased in phagocytic index when compared to control group. This indicates stimulation 
of the reticuloendothelial system. 
Table 3. Effect of A.indicum on Phagocytic activity by carbon clearance test. 
Treatment        Phagocytic Index 
Vehicle Control                     0.029 ± 0.0004 
AEAI 0.017  ±  0.0002** 
EEAI       0.076 ± 0.0009** 
LMS      0.083 ± 0.001** 
Values are expressed as ( Mean ± S.E.M.), n= 5, **p<0.01. All groups were compared with control group.  
Neutrophil adhesion test 
Effect of AIAE and AIEE on neutrophil activation by the neutrophil adhesion test is shown in [Table 4]. 
Cytokines are secreted by activated immune cells for margination and extravasation of the phagocytes mainly 
polymorphonuclear neutrophils. The percentage neutrophil adhesion was significantly (p<0.01) increased by 
AEAI (400 mg/kg/p.o.) and EEAI (200 mg/kg/p.o.) when compared with the control group, showed possible 
immunostimulant effect. AI significantly evoked increase in the adhesion of neutrophils to nylon fibers which 
correlates to the process of margination of cells in blood vessels.  
Table  4. Effect of A.indicum treatment on neutrophil activation by neutrophil adhesion test. 
Treatment        % Neutrophil Adhesion  
Vehicle Control                     29.25± 0.57 
AEAI 42.08±0.61** 
EEAI       44.87± 1.42** 
LMS      73.24±0.06** 
Values are expressed as ( Mean ± S.E.M.), n= 5, **p<0.01. All groups were compared with control group. 
Statistically analysed by one- way analysis of variance (ANOVA) followed by Tukey-Kramer multiple 
comparison test. 
DISCUSSION 
Immunomodulation is a procedure which can alter the immune system of an organism by interfering with its 
functions; if it results in an enhancement of immune reactions it is named as an immunostimulative drug which 
primarily implies stimulation of specific and non specific system, i.e. granulocytes, macrophages, complement, 
certain T-lymphocytes and different effector substances. Immuno-suppression implies mainly to reduce 
resistance against infections, stress and may occur on account of environmental or chemotherapeutic factor.
 [19] 
The results obtained in the present study indicate that AI is a potent immunostimulant, stimulating specific and 
non-specific immune mechanisms.  
The humoral immunity involves interaction of B cells with the antigen and their subsequent proliferation and 
differentiation into antibody-secreting plasma cells. Antibody functions as the effector of the humoral response 
by binding to antigen and neutralizing it or facilitating its elimination by cross-linking to form clusters that are 
more readily ingested by phagocytic cells. To evaluate the effect of AI on humoral response, its influence was 
tested on sheep erythrocyte specific HA titre in mice.
 [20] Cyclophosphamide showed significant inhibition in 
antibody titre response, while AEAI and EEAI counteract the suppression of both primary and secondary 
humoral responses induced by cyclophosphamide.
 [21] This indicates the enhanced responsiveness of 
macrophages, T and B lymphocyte subsets involved in antibody synthesis.  
Cell-mediated immunity (CMI) involves effector mechanisms carried out by T lymphocytes and their products 
(lymphokines).
 [22] DTH requires the specific recognition of a given antigen by activated T lymphocytes, which 
subsequently proliferate and release cytokines. These in turn increase vascular permeability, induce 
vasodilatation, macrophage accumulation, and activation, promoting increased phagocytic activity and increased 
ISSN : 0975-9492 182N.L. DASHPUTRE et. al. / International Journal of Pharma Sciences and Research (IJPSR) 
Vol.1(3), 2010, 178-184 
concentrations of lytic enzymes for more effective killing. When activated TH1 cells encounter certain antigens, 
viz. SRBCs. They secrete cytokines that induce a localised inflammatory reaction called delayed type 
hypersensitivity.
[23] DTH comprises of two phases, an initial sensitisation phase after the primary contact with 
SRBC antigen. During this period TH1 cells are activated and clonally expanded by APC (antigen presenting 
cells) with class II MHC molecule (eg. langerhans cells and macrophages are APC involved in DTH  response). 
A subsequent exposure to the SRBCs antigen induces the effector phase of the DTH response, where TH1 cells 
secrete a variety of cytokines that recruits and activates macrophages and other non specific inflammatory 
mediators. The delay in the onset of the response reflects the time required for the cytokines to induce the 
recruitment and activation of macrophages.
[24] Therefore, increase in DTH reaction in mice in response to T cell 
dependent antigen revealed the stimulatory effect of AEAI and EEAI on T cells.  
The role of phagocytosis is the removal of microorganisms and foreign bodies, dead or injured cells. The 
increase in the carbon clearance index reflects the enhancement of the phagocytic function of mononuclear 
macrophage and nonspecific immunity. Phagocytosis by macrophages is important against the smaller parasites 
and its effectiveness is markedly enhanced by the opsonisation of parasites with antibodies and complementing 
C3b, leading to a more rapid clearance of parasites from the blood.
 [25] AI appeared to enhance the phagocytic 
function by exhibiting a clearance rate of carbon by the cells of the reticulo-endothelium system.  
Cytokines are secreted by activated immune cells for margination and extravasation of the phagocytes mainly 
polymorphonuclear neutrophils. Significantly evoked increase in the adhesion of neutrophils to nylon fibers 
which correlates to the process of margination of cells in blood vessels.
[16] In the present study, AI evoked a 
significant increase in percent of neutrophils. This may help in increasing immunity of body against microbial 
infections. 
Since AI was found to have a significant immunostimulatory activity on both the specific and non-specific 
immune mechanisms. The significant increase in the immunostimulatory activity of AI could be attributed to the 
presence of flavonoids (quercetin), alkaloids, tannins, saponin glycosides and phenolic compounds. Therefore, 
the plant holds promise for being used as an immunostimulating agent and an in-depth study on various 
fractions of the extract effective as immunomodulating entities from the plant is warranted to determine the 
most potent immunostimulating fraction from AI. Thus, the study validates the traditional use of AI as a 
‘Rasayana’ in Ayurvedic system of medicine. 
CONCLUSION  
The results of the present study suggest that the aqueous and ethanolic extracts of A. indicum leaves may be 
beneficial in the treatment of impaired immunity. Further studies to identify the active moieties and elucidation 
of the mechanism of action are recommended. 
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